Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

June 15, 2025

Study Completion Date

February 15, 2029

Conditions
Bladder Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy

Trial Locations (12)

94800

Gustave Roussy, Villejuif

Unknown

Institut Bergonie, Bordeaux

Centre Jean Perrin, Clermont-Ferrand

Centre Georges Francois Leclerc, Dijon

Centre Oscar Lambret, Lille

Icm Val D'Aurelle, Montpellier

Centre Antoine Lacassagne, Nice

Hopital Saint Louis, Paris

Hôpital Pitie Salpetriere, Paris

Chu Lyon Sud, Pierre-Bénite

INSTITUT de CANCEROLOGIE DE L'OUEST - site René Gauducheau, Saint-Herblain

06250

Centre Azureen de Cancerologie, Mougins

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

UNICANCER

OTHER

NCT03697850 - Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | Biotech Hunter | Biotech Hunter